I am going to my transplant screening day tomorrow (not the list screening, but the final screening for the clinical trial) and because of this discussion, I decided to look into my status. I am EBV+/CMV-. For some reason, they do not know what Gwyn (my donor) is, I think they didn't bother to test because it is apparently a costly lab. I did, however, research this and found this article. It is old - almost 10 years - but it mentions the same transplant drugs I will be taking, and that most people take (Cellcept, Prograf). Here is the link:
http://jasn.asnjournals.org/cgi/reprint/12/4/848.pdfThe sentences that leapt out at me are:
"Historically, concern has focused mainly on avoiding CMV
infection in the CMV D+/R- group because this group has
been at greatest risk for severe “primary” infection during the
first 3 mo after transplantation. However, the indirect effects of
CMV infection on graft and patient survival have been increasingly
recognized in recent years. Our own analyses of data
from the United States Renal Data System and United Network
of Organ Sharing revealed that by 3 yr, it is the D+/R+ group
and not the D+/R- group that has the worst graft and patient
survival (16,17). The reason for this is not entirely clear but
may reflect the prevalence of multiple CMV virotypes and that
the D+/R+ patients may have a double CMV exposure with
reactivation of differing latent donor and recipient CMV."
(In case you hadn't figured it out D=donor, R=recipient)
I will be asking the surgeon about this tomorrow if possible and will let everyone know if I find out anything new. I imagine that EBV and CMV both behave similarly, so if Gwyn and I are both EBV+ it seems that could be just as bad overall as if I am CMV- and he is CMV+.